What Drives Health-Care Spending Priorities? An International Survey of Health-Care Professionals

Salkeld, Glenn; Henry, David; Hill, Suzanne; Lang, Danielle; Freemantle, Nick; d'Assuncao, Jefferson

doi:10.1371/journal.pmed.0040094

Cited by 11 publications

(8 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results in this present study show that this is currently not the case at all. The continued use of this dimension of effectiveness in clinical trials could lead to a better evaluation of priorities in the treatment of chronic diseases [70].…”

Section: Discussionmentioning

confidence: 99%

Measuring health-related quality of life in drug clinical trials: is it given due importance?

Miguel¹,

López-González

Iriso

et al. 2007

Pharm World Sci

View full text Add to dashboard Cite

HRQL measures are not used on a regular basis in drug clinical trials that are reported in the relevant literature. Systematic incorporation of QOL measures into clinical trials would make it possible to measure the benefit obtained from drug treatments taking into account the patients' perceptions. Moreover, it would encourage the development of prospective cost-effectiveness studies with patient recorded data in the context of clinical trials. Our findings have a direct impact on practice. Being conscious of the low use of HRQL in clinical trials, it could contribute to increase the demand for these measures by health care professionals. The manuscript is also a useful tool to identify where basic concepts about HRQL measures can be found.

show abstract

Section: Discussionmentioning

confidence: 99%

Measuring health-related quality of life in drug clinical trials: is it given due importance?

Miguel¹,

López-González

Iriso

et al. 2007

Pharm World Sci

View full text Add to dashboard Cite

show abstract

“…Irrespective of efficiency, it is anticipated that the provision of prenatal and diagnostic tests for congenital deafness will increase as a component of routine genetics services, and that demand for such testing will grow as the genetic basis for the development of this condition is further realized [13, 23, 24]. This may well be consistent with societal objectives, where children’s issues are ranked high in terms of community priorities [25]. …”

Section: Discussionmentioning

confidence: 99%

Parental Perspective of the Benefits of Genetic Testing in Children with Congenital Deafness

Geelhoed

Harrison²,

Davey³

et al. 2009

Public Health Genomics

View full text Add to dashboard Cite

Aim: The aim of the study was to assess the perceived value of genetic testing for congenital deafness in families attending a clinical genetic outpatients department at a children’s hospital. The major testing objective was to provide information regarding deafness etiology, although families were advised that changes in treatment as a result of the test were unlikely. Using a ‘willingness-to-pay’ approach in the form of a questionnaire developed by Ryan et al. [J Med Genet 2003;40:1–5], parents were surveyed for their attitudes and willingness to pay for genetic testing. Results: Forty-nine families provided data for analysis, representing 56% of clinic attendances throughout the period. Most of the parents were themselves unaffected by hearing loss (93%) and none were deaf, although almost a quarter (22%) reported a family member born deaf. Parents considered the major benefit gained from testing was to better achieve clarity of understanding arising from discussion and the possible ascertainment of etiology. The average sum parents were willing to pay for genetic testing was 200 Australian dollars (AUD, 2007) or approximately 123 euros (EUR), ranging from 150 to 295 AUD according to ability to pay (as measured by gross income). However, the amount that even the highest income level were willing to pay underestimated the full economic cost of genetic testing. Conclusion: Genetic testing for deafness is highly valued by affected families despite the current limited overall expectation of definitive genetic diagnosis or changes in treatment. Parents considered the major benefits to be a better understanding of congenital deafness and the potential for assignment of causality.

show abstract

“…Therefore, gaining a better understanding of key actors’ perspectives (as depicted in Figure ) is vital in identifying the factors that drive investment decisions and in overcoming any perceived barriers to the implementation of evidence‐based prevention strategies into practice and policy 10,15–17 . For this study, we explored how decision makers (policy makers, insurers and funders) use economic evidence to inform investment in the prevention of lifestyle related NCDs, and identified how economic evidence can better match their needs.…”

mentioning

confidence: 99%

Exploring the use of economic evidence to inform investment in disease prevention – a qualitative study

Liu

Muhunthan

Ananthapavan

et al. 2018

Australian and New Zealand Journal of Public Health

View full text Add to dashboard Cite

Objective: In the context of growing financial pressures on health budgets, cost-effective prevention strategies are needed to address the burden from non-communicable disease in Australia. We explored how decision makers use economic evidence to inform such investment and how such evidence generated can more effectively meet the needs of end users.Methods: Thematic analysis of in-depth interviews with 15 high level stakeholders (Treasury, state health departments and the insurance industry), supplemented by documentary analysis.Results: Types of prevention approaches and economic evidence relevant to decision makers differed by organisational perspective. Capacity building in understanding economic evaluations and research evidence that addresses the differing criteria for investment used by different organisations is needed. The task of determining investment priorities in disease prevention comes with significant challenges including ideological barriers, delayed outcome measures, and implementation uncertainties. Conclusions and Implications for public health:Promoting the greater use of economic evidence in prevention requires more work on two fronts: tailoring the methods used by economists to better match the organisational imperatives of end users; and promoting greater consideration of broader societal and health sector perspectives among end users. This will require significant infrastructure development, monitoring and evaluation, stronger national leadership and a greater emphasis on evidence coproduction.

show abstract

What Drives Health-Care Spending Priorities? An International Survey of Health-Care Professionals

Abstract: The authors set out to compare spending priorities for health care, across a selection of largely middle-income countries, through a survey of current and future decision makers.

Cited by 11 publications

References 11 publications

Measuring health-related quality of life in drug clinical trials: is it given due importance?

Measuring health-related quality of life in drug clinical trials: is it given due importance?

Parental Perspective of the Benefits of Genetic Testing in Children with Congenital Deafness

Exploring the use of economic evidence to inform investment in disease prevention – a qualitative study

Contact Info

Product

Resources

About